Home / Business and Economy / Balaxi Pharmaceuticals' Net Profit Plummets 95% in Q2 2025
Balaxi Pharmaceuticals' Net Profit Plummets 95% in Q2 2025
11 Nov
Summary
- Balaxi Pharmaceuticals' net profit declined 95.42% in Q2 2025
- Sales dropped 27.40% to Rs 56.18 crore in Q2 2025
- Operating profit margin fell from 13.69% to 2.06% in Q2 2025
In the quarter ended September 2025, Balaxi Pharmaceuticals faced a significant decline in its financial performance. The company's net profit plummeted 95.42% to Rs 0.21 crore, down from Rs 4.59 crore in the previous quarter ended September 2024.
The primary driver behind this steep drop in profitability was a 27.40% decline in sales, which fell from Rs 77.38 crore in Q2 2024 to Rs 56.18 crore in Q2 2025. This sales decline also led to a sharp contraction in the company's operating profit margin, which fell from 13.69% in the previous year's quarter to just 2.06% in the current quarter.
Despite the challenging market conditions, Balaxi Pharmaceuticals continues to operate in the pharmaceutical sector, focusing on the development and distribution of its products. The company will need to address the factors behind its recent performance decline to regain its financial footing and deliver stronger results in the future.
